Scale-up and Clinical Bioavailability Assessment of a 45% Drug Loaded Amorphous Nanoparticle Formulation of a BCS IV Compound for Oral Delivery.

Abstract

A 45% drug loaded (DL) amorphous nanoparticle (ANP) formulation for a BCS IV drug demonstrated promising pharmacokinetics in dogs (Purohit, et al, J. Pharm. Sci. 2023(113)1007-1019). This preclinical data enabled a human proof-of-concept assessment opportunity. The ANP freeze dried powder for oral suspension was prepared using solvent/antisolvent precipitation followed by organic solvent removal and freeze drying (FD). Challenges manifested during scale-up from 50g to 280g. Given the preclinical data, formulation change was restricted, therefore, process modifications were implemented. Cold collection after precipitation prevented particle growth but resulted in 75 nm particles at clinical scale (CS), compared to 150 nm at laboratory scale (LS). This size decrease rendered stabilizer amounts suboptimal for FD operation. Consequently, when FD powder was resuspended in water a smaller fraction of particles was below 450 nm (by filtration), ∼65% for CS compared to ∼85% for LS. Formulation was stable for > 6 months, evaluated by monitoring moisture content, assay, powder X-ray diffraction (PXRD), and redispersion time. Despite ∼65% re-dispersibility, this 45% DL formulation in humans had higher C_max and AUC ∼73% and ∼46% respectively in fasted-state, and under fed-state it met bioequivalence criteria for AUC but C_max was 20% lower compared to reference (10% DL ASD tablets) demonstrating advantage of ANP strategy over ASD approach.